Activating BD&L and Open Innovation with MSD


Reserve your seat
With a broad focus across human and animal health, MSD’s BD&L teams are tasked with searching the world for cutting-edge science, regardless of therapeutic area or modality. In this webinar, Daniel Marshall, Director of Oncology Business Development at MSD, will join Inpart to explain how MSD integrates BD&L with Open Innovation and what it’s like to partner with one of the world’s largest pharma companies.
In the crucial weeks before BIO 2025, Daniel will offer strategies and tactics for early-stage biotechs and academic innovators seeking to connect with top pharma companies, as well as tips on how to get a foot in the door at the world’s largest partnering event.
Panelists

Join this webinar to learn:
- The key components of MSD’s BD&L and Open Innovation strategies
- What it's like to partner with a top global pharma company
- How MSD works towards being a Partner of Choice
- How to secure meetings with MSD and other top pharma companies at major conferences
About MSD
For more than 130 years, MSD (known as Merck & Co. in the United States and Canada) has delivered invaluable medicines and vaccines. The company aspires to be the premier research-intensive biopharmaceutical organization in the world—and today, it stands at the forefront of research, delivering innovative health solutions that advance the prevention and treatment of diseases in both people and animals.